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Dendritic cells (DCs) constantly sample peripheral tissues for antigens, which are subse-
quently ingested to derive peptides for presentation to T cells in lymph nodes. To do so, DCs
have to traverse many different tissues with varying oxygen tensions. Additionally, DCs are
often exposed to low oxygen tensions in tumors, where vascularization is lacking, as well as
in inflammatory foci, where oxygen is rapidly consumed by inflammatory cells during the res-
piratory burst. DCs respond to oxygen levels to tailor immune responses to such low-oxygen
environments. In the present study, we identified a mechanism of hypoxia-mediated po-
tentiation of release of tumor necrosis factor α (TNF-α), a pro-inflammatory cytokine with
important roles in both anti-cancer immunity and autoimmune disease. We show in hu-
man monocyte-derived DCs (moDCs) that this potentiation is controlled exclusively via the
p38/mitogen-activated protein kinase (MAPK) pathway. We identified MAPK kinase kinase 8
(MAP3K8) as a target gene of hypoxia-induced factor (HIF), a transcription factor controlled
by oxygen tension, upstream of the p38/MAPK pathway. Hypoxia increased expression of
MAP3K8 concomitant with the potentiation of TNF-α secretion. This potentiation was no
longer observed upon siRNA silencing of MAP3K8 or with a small molecule inhibitor of this
kinase, and this also decreased p38/MAPK phosphorylation. However, expression of DC
maturation markers CD83, CD86, and HLA-DR were not changed by hypoxia. Since DCs
play an important role in controlling T-cell activation and differentiation, our results provide
novel insight in understanding T-cell responses in inflammation, cancer, autoimmune dis-
ease and other diseases where hypoxia is involved.
Introduction
Dendritic cells (DCs) are the gatekeepers of the adaptive immune system, residing throughout periph-
eral tissues where they constantly sample for antigens [1,2]. When a DC encounters a foreign antigen,
it secretes many inflammatory cytokines, including tumor necrosis factor α (TNF-α), that activate or
repress the functions of other immune cells and contribute to an inflammatory disease state. Extracel-
lular antigens can be ingested by endocytosis or phagocytosis, processed in the endolysosomal system
and presented on MHC classes I and II on the surface of DCs. During this process, DCs traverse from
the site of inflammation to the nearest draining lymph node, where they activate naive CD4+ and CD8+
T cells [3]. For the sampling of antigen and the traveling to the lymph node, a DC can pass many dif-
ferent tissues that display a wide range of oxygen levels, from almost atmospheric oxygen levels in the
lung (20%) to hypoxic (<1%) oxygen tensions in the thymus and spleen [4]. On top of this, many disease
states are characterized by low local oxygen levels. For example, the central region of solid tumors is very
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hypoxic due to a lack of vascularization [5,6]. Moreover, sites of infection and inflammation are often hypoxic mi-
croenvironments, due to the combination of reduced perfusion following physical damage and the high metabolic
load of the activated inflammatory cells caused by the respiratory burst [7,8]. Hypoxia has been linked to many
auto-inflammatory diseases, including diabetes and atherosclerosis [9–11]. In cancer, hypoxia induces the neovas-
cularization that can promote tumor growth and possibly cancer cell metastasis [6]. Hypoxia can also be a direct
driver of metastasis by inducing single-cell dissemination [12].
Oxygen levels are known tomodulatemany cellular processes, includingmetabolism, cell survival, and various sig-
naling pathways [13,14]. The most important class of oxygen-sensitive signaling proteins is hypoxia-induced factor
(HIF). HIFs are basic helix–loop–helix heterodimeric transcription factors involving three main subunits: HIF-1α,
HIF-2α, and HIF-1β [13–15]. All three subunits are constitutionally expressed, but under normoxic conditions pro-
line residues on the α-subunits are modified by prolyl hydroxylases (PHDs) in a process that consumes oxygen.
After this hydroxylation, the von Hippel–Lindau E3 ligase (VHL) can trigger ubiquitination of the α-subunit leading
to subsequent proteasomal degradation [13]. Under hypoxic conditions, PHD does not efficiently hydroxylate the
α-subunit due to lack of oxygen, allowing HIF-1α or HIF-2α to dimerize with HIF-1β. These HIF complexes will
then promote transcription of genes carrying hypoxic response elements (HREs) in their promoter regions [16–18].
Oxygen levels regulate the mammalian immune response, as it was recently shown that mice negative for HIF-1α
fail to clear invasive bacterial infections [18]. Oxygen levels also modulate DC differentiation and the activation
triggered by maturation stimuli such as lipopolysaccharide (LPS), a bacterial ligand of Toll-like receptor 4 (TLR4)
[9,18–35]. Specifically, hypoxic DCs were shown to have increased levels of HIF-1α, metabolism shifted to glycolysis
[30,31,33], and altered expression of chemokines and chemokine receptors affecting DC migration [27,28,30,32,34].
The effect of hypoxia on the expression of DC-maturation markers (e.g., CD80, CD83, CD86, MHC-II) is controver-
sial, with both reductions [19,21,25–27,29,32], increases [30,31], and no effect [28,35] being reported. Similarly, both
increased [31] and reduced [27,32] efficiencies of T-cell activation by hypoxic DCs, and both stimulatory [19,31,32]
and inhibitory [21,25,27] effects of hypoxia on TLR-induced cytokine release (e.g., interleukin (IL)-6, IL-10, IL-12,
TNF-α) have been reported.
The controversial findings of hypoxia on DC function likely arise from the fact that HIF not only modulates
TLR signaling [36], but TLR stimulation in turn also affects HIF signaling [20,22,37]. TLR stimulation can pro-
mote the stabilization of HIF as well as up-regulate its expression [20,22]. The group of target genes regulated by
HIF differs between activation of HIF via TLR stimulation or hypoxia [22] and this cross-talk between HIF and
TLR signaling likely allows for fine-tuning of the cellular immune responses against different types of infections
and disease states. However, the molecular mechanisms of the interplay between TLR and hypoxic signaling are still
largely unknown. In the present study, we describe a pathway by which hypoxia potentiates TNF-α secretion by hu-
man monocyte-derived DCs (moDCs). MoDCs are differentiated from blood-isolated monocytes by culturing with
IL-4 and granulocyte-macrophage colony-stimulating factor (GM-CSF). Although their physiological role is unclear,
moDCs are capable of migration to lymph nodes and of both MHC-I and II presentation [19,23–28,30,32–35]. We
show an increase in LPS-induced secretion of TNF-α bymoDCs upon hypoxia, in line with previous findings [31,32].
Our data show that this potentiation is caused by hypoxia-promoted expression of mitogen-activated protein kinase
(MAPK) kinase kinase 8 (MAP3K8; TPL-2; COT), which is a kinase involved in theMAP3K signaling pathway down-
stream of TLR4. Given the essential roles of DCs in T-cell activation and differentiation, our results are important for
understanding T-cell responses in cancer, infection, autoimmunity, and other diseases and disorders associated with
hypoxia.
Experimental
Cells and culture conditions
MoDCs were derived from peripheral blood mononuclear cells (PBMCs) obtained from buffy coats of healthy indi-
viduals as described previously [38]. Approval to conduct experiments with human blood samples was obtained from
the blood bank and all experiments were conducted according to national and institutional guidelines. Informed con-
sent was obtained from all blood donors by the Dutch blood bank. Samples were anonymized and none of the inves-
tigators could ascertain the identity of the blood donors. Briefly, peripheral blood leukocytes (PBLs) were separated
from monocytes by a 1-h adhesion step at 5% CO2 and 37◦C in RPMI-1640 (Thermo Fisher Scientific, Waltham,
U.S.A.) with 2% human serum. Monocytes were differentiated into DCs by culturing for 6 days at 5% CO2 and
37◦C in RPMI-1640 (Thermo Fisher Scientific) with 300 U/ml IL-4, 450 U/ml GM-CSF, 10% FBS (Greiner Bio-one,
Kremsmu¨nster, Austria), 2mMUltraGlutamine (Lonza, Basel, Switzerland), and 1% antibiotic-antimycotic (Gibco by
Life Technologies, Kremsmu¨nster, Austria). For hypoxic culture, moDCs were kept overnight at 1% O2, 5% CO2, and
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94% N2 at 37◦C (CB53 incubator, Binder, Tuttlingen, Germany) in complete RPMI-1640 (Thermo Fisher Scientific)
with 10% FBS (Greiner Bio-one), 2 mM UltraGlutamine (Lonza, Basel, Switzerland), and 1% antibiotic-antimycotic
(Gibco by Life Technologies). For normoxic culture, cells were kept at atmospheric O2 (20%) with 5% CO2. To acti-
vate the DCs, 1 μg/ml of LPS (LPSs from Escherichia coli 0111:B4, Sigma–Aldrich, St. Louis, U.S.A.) was added to
the medium. To quantitate cytokine production, cell culture supernatants were collected and stored at −80◦C until
analysis with IL-6 and TNF-α-specific ELISA (eBioscience, San Diego, U.S.A.).
Inhibitors and antibodies
To inhibit p38 signaling, we used 1 μM SB203580 (Cell Signaling Technology, Danvers, U.S.A.). To inhibit IκB ki-
nase (IKK), we used 100 nM IKK-16 (R&D Systems, Minneapolis, U.S.A.), to inhibit MAP3K8 we used 1 μM of
Tpl2 kinase inhibitor (Cayman Chemical, Ann Arbor, U.S.A.), to inhibit Erk1/2 we used 250 nM of CAY10561
(Cayman Chemical). Primary antibodies used were: mouse-IgG1 anti-MAP3K8 (sc-373677, Santa Cruz Biotechnol-
ogy, Dallas, U.S.A.), rabbit monoclonal IgG anti-p38/ MAPK (8690, Cell Signaling Technology), rabbit monoclonal
IgG anti-p-p38/MAPK (Thr180/Tyr182) (4511, Cell Signaling Technology), rabbit polyclonal anti-p44/p42 MAPK
(Erk1/2) (Cell Signaling Technology), mouse-IgG1 anti-p-p44/p42 MAPK (Erk1/2) (Thr202/Tyr204) (Cell Signaling
Technology), rabbit monoclonal IgG anti-GAPDH (2118, Cell Signaling Technology). The following secondary an-
tibodies were used: goat anti-rabbit or anti-mouse IgG (H+L) IRDye 800 CW (926-32211, 926-32210, LI-COR Bio-
sciences, Lincoln, U.S.A.). Cell death was assessed with Zombie Violet fixable viability dye (BioLegend, San Diego,
U.S.A.). The following directly labeled antibodies were used: CD11c-FITC (BD Biosciences, Franklin Lakes, U.S.A.),
CD14-PE-Cy7 (Miltenyi Biotec, BergischGladbach, Germany), CD16-APC (Miltenyi Biotec), CD11b-PE-Cy7 (Beck-
man Coulter, Brea, U.S.A.), CD68-APC (BioLegend), HLA-DR-PE (BD Biosciences), CD83-FITC (BD Biosciences),
CD86-APC (BD Biosciences), TLR2-FITC (BioLegend), TLR4-APC (BioLegend).
Western blot
SDS/PAGE with Western blot was used to analyze MAP3K8 knockdown efficiency and phosphorylation of p38 and
Erk1/2 using 10% acrylamide gels. Proteins were then transferred to PVDF membranes (Immobilon-FL 0.45 μm,
Merck, Burlington, U.S.A.), blocked for 1 h with 5% BSA in Tris/HCl-buffered saline and incubated overnight with
primary antibodies (1:200 to 1:500 dilution). These were labeled by incubating with IRDye800–conjugated secondary
antibodies (1:5000 dilution; LI-COR Biosciences) and analyzed using the Odyssey CLx Infrared Imaging System and
ImageStudio Lite 5.0 analysis software (LI-COR Biosciences).
Flow cytometry
For flow cytometry assays, moDCs were seeded at 100,000 cells per well in 100 μl of complete RPMI in a V-bottom
96-well plate. After incubation at hypoxic or atmospheric oxygen levels and with or without inhibitors, as described
above, cells were centrifuged at 1500 rpm for 2 min at 4◦C. Supernatant was discarded and cells were incubated for
30 min in the dark with PBS containing Zombie Violet fixable viability stain (BioLegend, 1:2000 dilution), then fixed
with 4% PFA for 2 min and incubated for 10 min in the dark on ice with 50 μl of phosphate-buffered azide (PBA; PBS
containing 0.5%BSA and 0.01%NaN3) containing 1% human serum to block Fc receptors. Then, cells were incubated
for 30 min in the dark on ice with 50 μl of PBA containing directly labeled antibodies. To perform compensation and
set gates, AbC Total Antibody Compensation beads (Thermo Fischer Scientific) were stained in the same way as the
cell samples. Cells were washed with 100 μl PBA, resuspended in 60 μl PBA, and analyzed on a FACSCalibur or
FACSVerse flow cytometer (BD Biosciences).
Transfections
DCs were electroporated with siRNA against MAP3K8 (a 1:1:1 mix of GGCGUGUAAACUGAUCCCAGUAGAU,
GGAAGGAGCUGGAACUUCCUGAGAA, and UGGUUGUCAUCAGUCAGAUAUGGAA; Thermo Fischer Sci-
entific) using a Neon electroporation system (Thermo Fischer Scientific). Briefly, DCs were thawed from liquid ni-
trogen storage, washed once with PBS and resuspended in R buffer (from the Neon kit) at 0.5–1.0 × 106 cells in 120
μl volume. Four micrograms of plasmid DNA or 20 pmol siRNA mix was added and the cells were electroporated
with two pulses of 1000 V at 40 ms pulse width. Cells were then transferred to pre-warmed RPMI-1640 containing 2
mMUltraGlutamine. Four hours post transfection, an equal amount of complete RPMI-1640 was added to the cells.
Experiments were performed 24 h post-transfection.
c© 2018 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Primers and PCRs
MAP3K8 expression in untreated moDCs was checked with PCR on cDNA using primers for MAP3K8 (CTC-
CCCAAAATGGACGTTACC and GGATTTCCACATCAGATGGCTTA). Expression levels were quantitated with
real-time quantitative PCR (RT-qPCR) using validated primers forMAP3K8 (GAGCGTTCTAAGTCTCTGCTG and
GCAAGCAAATCCTCCACAGTTC), TBP (GAGCCAAGAGTGAAGAACAGTC and GCTCCCCACCATATTCT-
GAATCT) and GUSB (GACACGCTAGAGCATGAGGG and GGGTGAGTGTGTTGTTGATGG). Briefly, mRNA
was isolated from DCs using a Quick-RNA MiniPrep Plus kit (Zymo Research, Irvine, U.S.A.) and cDNA was gen-
erated in a standard reverse transcriptase reaction. qPCRs were done on a CFX96 Real-Time PCR Detection System
(Bio-Rad, Hercules, U.S.A.), using FastStart SYBR Green Master mix (Hoffmann-La Roche, Basel, Switzerland) and
analyzed in CFX Manager software version 3.1 (Bio-Rad, Hercules, U.S.A.). Gene expression was first normalized
(Cq) to housekeeping genes (TBP and GUSB) validated with geNorm analysis, followed by normalization to
untreated samples.
Statistical analysis
For datasets with two paired conditions, paired two-sided Student’s t tests were applied to assess significance when
data followed a normal distribution, otherwise Wilcoxon’s matched pairs signed-rank tests were used. One-way
ANOVA with Bonferroni’s post-hoc tests were applied for multiple comparisons. Box plots indicate mean with
whiskers depictingminimal andmaximal values. A value of P<0.05 was considered statistically significant (*P<0.05,
**P<0.01, ***P<0.001).
Results
TLR4-triggered TNF-α secretion is potentiated by hypoxia
We started by studying the interplay of hypoxia and infection on the secretion of IL-6 and TNF-α. We used DCs
differentiated frommonocytes isolated from the blood of healthy volunteers by culturing in the presence of IL-4 and
GM-CSF (moDCs). MoDCs are capable of endocytosis, phagocytosis, antigen (cross-)presentation and activation of
T cells, and are a widely used model system for studying hypoxia on DC function [19,23–28,30,32–35]. Although
moDCs are also found in vivo, they differ from conventional blood-circulating DC subsets and there has been an
ongoing debate about their exact physiological role [39–41]. We characterized our moDC cultures by measuring ex-
pression of severalDC,monocyte andmacrophage surfacemarkers.MoDCswere found to be a homogeneous popula-
tion of CD11c+/CD11b+/CD16−/CD68− cells, of which∼87% also expressed CD14+ (Supplementary Figure S1A–I).
These results show that our cells are composed mainly of DC-like cells which express high levels of the DC marker
CD11c. Monocytic lineage markers CD14 and CD11b were also highly expressed, whereas only low expression of the
monocyte/macrophagemarkers CD16 and CD68 was observed. ThemoDCs were cultured in a hypoxic environment
of 1% oxygen, or in an atmospheric environment of 20% oxygen. Similar to previous reports [19,25,28,31,35], flow
cytometry experiments showed that culturing DCs overnight under hypoxic conditions did not significantly affect
cell viability (Figure 1A–C). Culturing under hypoxic conditions trended toward decreased CD14 expression and a
non-consistent increase in CD68 expression, however these differences are not significant. Expression of all other
tested surface markers was unaltered (Supplementary Figure S1J–S).
To stimulate an inflammatory response, we cultured the moDCs in the presence of LPS. Compared with LPS at
atmospheric oxygen levels, LPS with hypoxia did not result in significant changes in surface expression of thematura-
tionmarkers CD83 andCD86 (Figure 1D,E,G,H), as reported previously [26,28,30], but contrastingwith other studies
[19,21,25,31,32]. Surface levels of MHC-II were also not changed by hypoxia (Figure 1F,I), which again corresponds
with some studies [28,30], while other studies report higher [31] or lower [21,25–27,29,32] MHC-II levels upon hy-
poxia. We observed the strongest potentiation for production of TNF-α, where hypoxia resulted in an approximately
two-fold significant increase in LPS-triggered TNF-α secretion compared with atmospheric oxygen (Figure 1J). The
increase in LPS-induced IL-6 secretion upon hypoxia was not significant compared with atmospheric oxygen levels
(Figure 1K). A potentiation in TLR-stimulated TNF-α secretion by DCs upon hypoxia has been reported previously
in some [31,32], but not all [21,27], studies. Moreover, hypoxia-mediated potentiation of TNF-α secretion has been
observed for macrophages [17], osteoblasts [42], and human hepatocellular carcinoma cells [36].
SB203580, an inhibitor for p38/MAPK, blocks hypoxia-potentiated TNF-α
secretion
TLR4 stimulation triggers TNF-α secretion via two distinct signaling pathways. In the first pathway, TNF-α ex-
pression is up-regulated by activated nuclear factor κB (NF-κB) following IKK phosphorylation by TLR4. In the
4 c© 2018 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Figure 1. Hypoxia potentiates LPS-induced TNF-α secretion
(A–C) Cell viability of moDCs during atmospheric (20% O2) and hypoxic (1% O2) oxygen levels in presence or absence of LPS,
determined by Zombie Violet as analyzed by flow cytometry. Representative dot plot (A), histograms (B), and quantitation for three
donors ((C); average +− S.E.M.) are shown. (D–I) LPS-induced maturation of moDCs cultured at atmospheric or hypoxic oxygen
levels, determined by expression levels of maturationmarkers CD83 (D,G), CD86 (E,H), and HLA-DR (F,I). Representative histograms
showed quantitation for five donors. (J,K) Secretion by ELISA of the pro-inflammatory cytokines TNF-α (J) and IL-6 (K) from moDCs
cultured at atmospheric or hypoxic oxygen levels. Quantitation from ten donors (average+− S.E.M.). *P<0.05; **P<0.01; ***P<0.001.
Abbreviation: ns, not significant.
c© 2018 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Figure 2. Hypoxia-mediated potentiation of TNF-α secretion is controlled by p38/MAPK
(A–F) Effects of inhibitors of p38/MAPK (1 μM SB203580; (A,B,E,F)) and/or IKK (100 nM IKK-16; (C–F)) on LPS-induced TNF-α
secretion by moDCs cultured under atmospheric (20% O2; (A,C,E)) or hypoxic (1% O2; (B,D,F)) oxygen levels. Individual donors
shown. (G,H) Effects of SB203580 and/or IKK-16 on moDC viability, determined by flow cytometry labeling with Zombie Violet
as analyzed by flow cytometry. Representative histograms (G) and quantitation for four donors ((H); average +− S.E.M.). *P<0.05;
**P<0.01; ***P<0.001. Abbreviaton: ns, not significant.
second pathway, TNF-α secretion is mediated via p38/MAPK signaling, which is activated in tandem with NF-κB
following TLR4 stimulation [43,44]. We used specific inhibitors to elucidate the contribution of each pathway in
the hypoxia-mediated potentiation of TNF-α secretion. Inhibition of p38/MAPK with SB203580, which inhibits the
downstream catalytic activity of p38 [45,46], did not affect LPS-triggered TNF-α secretion under atmospheric oxygen
levels (Figure 2A). In contrast, under hypoxic conditions, SB203580 resulted in a consistent and significant reduction
in TNF-α secretion (Figure 2B). Blockage of IKK, which is responsible for activation of NF-κB [47,48], by IKK-16
blocked TNF-α secretion almost completely (to∼20% of untreated) both under atmospheric and hypoxic conditions
(Figure 2C,D). Simultaneous addition of both SB203580 and IKK-16 had a comparable effect (Figure 2E,F). The resid-
ual TNF-α secretion might be due to incomplete inhibition of the NF-κB and/or p38/MAPK pathways or due to the
involvement of other signaling pathways. Under our conditions, SB203580 and IKK-16 did not affect the viability of
the cells (Figure 2G,H). These findings suggest that the hypoxia-mediated potentiation of TNF-α release primarily
occurs via increased activation of the p38/MAPK signaling pathway, while the IKK signaling pathway is activated
by LPS irrespective of oxygen levels. In-line with this, hypoxia was reported to promote TLR2 and TLR4-induced
pro-inflammatory activation of macrophages via the p38/MAPK pathway, but not via IKK signaling [49]. In contrast
with macrophages [50], surface expression of TLR2 and TLR4 was unaffected by hypoxia (Supplementary Figure
S2A–D), suggesting that the increased TNF-α secretion was not caused by increased expression of these pattern
recognition receptors.
To directly investigate the activation of the p38/MAPK pathway by hypoxia and LPS, we determined activation of
p38 by Western blot with phosphospecific antibodies (Figure 3A). As described previously, LPS treatment of DCs
leads to activation of p38 by phosphorylation of the residues Thr180 and Tyr182 [51]. In-line with this, we observed a
three- to four-fold increase in p-p38 upon LPS stimulation compared with unstimulated cells at atmospheric oxygen
levels. Culturing the cells under hypoxic conditions in presence of LPS led to a further significant increase in p38
phosphorylation by ∼50%, whereas this increase was non-significant in absence of LPS (Figure 3B).
MAP3K8 is an HIF target gene and is overexpressed at hypoxic
inﬂammation
Hypoxia is well-known to increase expression of genes with an HRE in their promoter via the transcription factor
HIF [15,16]. We therefore searched for genes coding for components in the p38/MAPK pathway carrying one or
more HREs in their promoter. We identified MAP3K8 as a candidate gene downstream of HIF, since it is known to
6 c© 2018 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Figure 3. LPS-induced phosphorylation of p38/MAPK is increased at hypoxia
(A) Representative Western blot of moDCs cultured at atmospheric (20% O2) or hypoxic (1% O2) oxygen levels and in presence or
absence of LPS. The blot was stained with an antibody specific for p-p38/MAPK (top) and total p38/MAPK (bottom). (B) Quantitation
of (A) for five donors. p38/MAPK phosphorylation during hypoxic inflammation, normalized to unstimulated cells at atmospheric
oxygen levels (LPS-, 20% O2). *P<0.05; **P<0.01; ***P<0.001. Abbreviation: ns, not significant.
have a HIF-1β binding site and is up-regulated under hypoxia [17,52,53]. Indeed, we identified three HREs and an
HIF-1-specific binding site upstream of the MAP3K8 gene on chromosome 10 (GenBank accession AL161651.13)
using PROMO (Figure 4A) [54,55]. Reverse transcriptase (RT-) PCR showed that MAP3K8 is expressed in moDCs
(Figure 4B).
Since MAP3K8 is a key mediator of p38/MAPK signaling, we hypothesized that the hypoxia-induced TNF-α po-
tentiation occurred via increased expression of MAP3K8. To address this hypothesis, we cultured moDCs under
atmospheric or hypoxic conditions and with or without addition of LPS, followed by mRNA isolation to analyze
expression of MAP3K8 by RT-qPCR. Hypoxia led to a significant approximately two-fold increased expression of
MAP3K8 in absence of LPS (Figure 4C). In the presence of LPS, this increase was even more pronounced and we
observed an average ∼14-fold increase in MAP3K8 expression. Overall, the expression of MAP3K8 mirrors the po-
tentiation of TNF-α secretion by a combination of LPS and hypoxia (Figure 1J) and is in qualitative agreement with
the increased phosphorylation of p38 (Figure 3B). These findings support our hypothesis that MAP3K8 potentiates
LPS-induced TNF-α secretion under hypoxic conditions.
MAP3K8 directly links HIF signaling to the p38/MAPK pathway
To obtain direct evidence that MAP3K8 is a key factor linking hypoxia to potentiation of LPS-stimulated TNF-α se-
cretion, we performed knockdown experiments inmoDCswhere we targettedMAP3K8with siRNA (MAP3K8siRNA).
As a negative control, we transfected the moDCs with non-targetting siRNA.With this technique, we obtained an av-
erage reduction in∼40% ofMAP3K8 at the protein level, as quantitated byWestern blot (Figure 5A,B).MAP3K8siRNA
blocked the hypoxia-mediated potentiation of LPS-stimulated TNF-α secretion (Figure 5C). Phosphorylation of p38
was also reduced inMAP3K8siRNA moDCs following LPS stimulation at hypoxic, but not at atmospheric oxygen levels
(Figure 5D,E).
We further validated the role of MAP3K8 in potentiation of TNF-α secretion with the small molecule in-
hibitor 4-[(3-chloro-4-fluorophenyl)amino]-6-[(3-pyridinylmethyl)amino]-1,7-naphthyridine-3-carbonitrile (Tpl2
kinase inhibitor). This molecule inhibits MAP3K8 by blocking binding of ATP to MAP3K8 [56] and did not af-
fect cell viability (Figure 5G). In-line with the results obtained with siRNA knockdown, we observed that overnight
incubation with this inhibitor together with LPS stimulation decreased the hypoxia-mediated potentiation of TNF-α
secretion (Figure 5F). We also investigated phosphorylation of p38/MAPK following incubation with this inhibitor
(Supplementary Figure S3A,B), andwhile we observed a reduction in LPS-mediated p38/MAPKphosphorylation un-
der hypoxic conditions, this was not statistically significant. Together, these findings support that MAP3K8 promotes
TLR-mediated TNF-α secretion under hypoxic conditions.
Another major downstream target of MAP3K8 is the MEK/Erk pathway, which is described in literature to pro-
mote neutrophil development and LPS-mediated TNF-α secretion [57–59]. Therefore, we also probed for Erk1/2
c© 2018 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Figure 4. Hypoxia increases expression of HIF target gene MAP3K8
(A) Positions and sequences of HRE and HIF-binding site (HIF-1) in the promoter region of human MAP3K8. (B) MAP3K8 mRNA
expression by moDCs as determined by PCR on cDNA obtained from unstimulated moDCs. Expected band size is 201 bp. (C)
mRNA expression levels of MAP3K8 in moDCs cultured at atmospheric or hypoxic conditions in absence or presence of LPS
determined by RT-qPCR. Quantitation from six donors. *P<0.05, **P<0.01, ***P<0.001.
phosphorylation in moDCs stimulated with LPS and cultured at hypoxic and atmospheric oxygen levels (Supple-
mentary Figure S3C,D). We used inhibitors for Erk1/2 (CAY10561) [60] andMAP3K8 (Tpl2 kinase inhibitor) in this
experiment and performed a TNF-α ELISA. MoDC viability was unaffected by these small molecule inhibitors (Sup-
plementary Figure S3 and Figure 5G). However, we observed only low and inconsistent activation of Erk1/2 following
LPS and this was not altered by hypoxic culture. In contrast, a positive control of starved HeLa cells exposed to serum
showed clear Erk1/2 phosphorylation. Moreover, the increased TNF-α secretion under hypoxic conditions was not
modified by inhibition of Erk1/2 (Supplementary Figure S3E). Phosphorylation of p38/MAPK was also unaffected
by this inhibitor (Supplementary Figure S3A,B). These results show that LPS-mediated activation of the p38 pathway
is specifically potentiated via MAP3K8 under hypoxic conditions.
8 c© 2018 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Figure 5. MAP3K8 knockdown in moDCs blocks hypoxia-induced potentiation of LPS-induced TNF-α secretion
(A) Representative Western blot of siRNA knockdown of MAP3K8 in moDCs (MAP3K8siRNA) stained with an antibody specific for
MAP3K8 (top) and loading control (GAPDH; bottom). MoDCs were transfected with non-targetting siRNA as negative control. (B)
Quantitation of (A) by band intensities normalized to GAPDH and shown relative to non-targetting control. Individual donors are
shown. Compared using Wilcoxon’s matched-pairs signed rank test. (C) TNF-α secretion by moDCs with or without MAP3K8siRNA
and cultured at atmospheric (20% O2) or hypoxic (1% O2) oxygen levels. Quantitation of 14 donors (average +− S.E.M.). (D) Phos-
phorylation of p38/MAPK in moDCs with or without MAP3K8siRNA and cultured at atmospheric (20%O2) or hypoxic (1%O2) oxygen
levels. Representative Western blot probed for phosphorylated and total p38/MAPK shown. (E) Quantitation of (D) for six donors.
Shown are the ratios of p38/MAPK phosphorylation for MAP3K8siRNA moDCs compared with non-targetting siRNA controls. (F)
TNF-α secretion by moDCs following overnight incubation with LPS and Tpl2 kinase inhibitor (Tpl2 KI) normalized to atmospheric
oxygen condition (average +− S.E.M.). (G) Representative flow cytometry histogram showing Zombie Violet cell viability staining
on moDCs incubated overnight with Tpl2 KI, DMSO negative control, or 2 min 70% ethanol (EtOH) as positive control. *P<0.05.
Abbreviation: ns, not significant.
c© 2018 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Discussion
Hypoxia is capable of both potentiating and suppressing the response of immune cells and other cells to TLR stimuli.
In primary humanmacrophages, the TLR2- and 4-induced expression and secretion of various pro-inflammatory cy-
tokines (amongst others IL-6, IL-8, and IL-1β) was shown to be increased by hypoxia. In osteoclasts, hypoxia induced
TNF-α expression and this depended onHIF-1α expression [42]. However, the effects of hypoxia on humanDC func-
tion are more controversial, and both the inhibition [21,25,27,32] as well as stimulation [19,31,32] of TLR-induced
cytokine secretion by hypoxia have been described (e.g., for IL-6, IL-10, IL-12, TNF-α). Antigen uptake by DCs was
shown to be less efficient in hypoxic DCs [27,30], although Bosseto et al. [19] showed that uptake was not affected
for Leishmania infections. The effects of hypoxia on the subsequent activation of T cells by DCs are equally con-
troversial, and Jantsch et al. [31] described an increase in activation, while others reported a decrease [27,32]. The
relatively modest effects observed in this study may explain the many contradictory reports on the effects of hypoxia
on immune cells.
The divergent effects of hypoxia on immune cell regulation are probably caused by the complex interplay of hypoxia
on intracellular signaling. In addition to the stabilization of HIF transcription factors, hypoxia causes a metabolic
shift toward anaerobic glycolysis, as also shown for DCs [61]. This metabolic shift can further affect the secretion
of cytokines, as shown for IL-1β secretion by macrophages [62]. Moreover, for immune phagocytes such as DCs,
TLR signaling can cause local hypoxia due to the large oxygen consumption by NAPDH oxidases that produce re-
active oxygen species (ROS) during the respiratory burst [20,24]. These ROS in turn can act as second messengers,
further modulating the transcriptional profile of immune cells, and for instance the hypoxia-induced activation of
NFκB is redox sensitive [63]. TLR-signaling can also directly affect HIF signaling via post-translational regulation
and increased expression of HIF [22,64–66]. Additionally, hypoxia was shown to up-regulate both HIF and TLR4
expression in macrophages [50] and synergistic induction of HIF-1α activity by hypoxia and TLR4 stimulation has
been shown in macrophages [67]. Finally, TNF-α can already induce HIF-1α expression under atmospheric condi-
tions [68]. All these interacting pathways make it difficult to discern cellular responses to hypoxia from those caused
by TLR signaling.
Because of the multifactorial responses of cells to hypoxia, the molecular mechanisms of hypoxia-mediated reg-
ulation of immune cell differentiation are still largely unknown. In corneal epithelial cells, the hypoxia-mediated
attenuation of NF-κB and Erk1/2 activation and of IL-6 and IL-8 secretion are dependent on myeloid differentiation
primary response gene 88 (MyD88) downstream of TLR4. In PC12 cells and primary human macrophages, the po-
tentiation of inflammatory cytokine secretion (IL-1β, IL-6, IL-8) by hypoxia is controlled specifically via p38/MAPK
and c-Jun N-terminal kinase (JNK) signaling, but not via IκBα [49,69]. In this study, we identified a new molec-
ular link between hypoxia and TLR signaling in human moDCs (Figure 6). We found that MAP3K8 expression is
directly regulated by hypoxia via several HREs, resulting in increased expression of MAP3K8 [17]. As the MAP3K8
kinase is involved in activation of the p38/MAPK pathway [70,71], its up-regulation results in increased transcrip-
tion of pro-inflammatory cytokines [57]. In this way, hypoxia-induced MAP3K8 up-regulation sensitizes the cells to
TLR stimulation. Since studies with MAP3K8 knockout mice demonstrated that long-term secretion of TNF-α, but
not IL-6, is regulated by MAP3K8 [72], our findings explain why hypoxia leads to a potentiation of TLR-stimulated
TNF-α secretion, but not or less of IL-6 secretion.
Cancer cells express p38/MAPK, and this pathway is activated by hypoxia [73,74]. MAPK signaling can induce
angiogenesis and metastasis, as well as tolerance by polarization of macrophages to the tolerogenic M2 subtype and
of T cells to Th17 cells [12,75]. In this way, MAP3K8 expression promotes tumor growth and progression as well
as immune suppression [76,77]. On the other hand, MAPK signaling can also have tumor suppressing functions: its
expression is associated with lung cancer patient survival via a p38 signaling pathway downstream of JNK [78] and
it suppresses colitis-associated tumorigenesis [79]. In-line with this, MAP3K8−/− mice show more tumor initiation
and faster progression of chemically induced skin cancer [80].
MAP3K8 is also involved in autoimmunity. For example, MAP3K8 links IL-17 receptor signaling to TAK1 activa-
tion, which leads to increased JNK, p38, andNFκB activity in Th17 cells, promoting autoimmune neuroinflammation
[81,82]. Moreover, MAP3K8 activity in T cells limits regulatory T cell (Treg) function by inhibiting FoxP3 expression
and lowering production of the immunosuppressive cytokines IL-10 and cytotoxic T lymphocyte-associated protein 4
(CTLA-4) [83]. In addition, TNF-α plays a pivotal role in a variety of autoimmune diseases, causing sustained inflam-
mation and tissue damage [84]. In many autoimmune diseases, a negative feedback loop between tissue damage and
inflammation exists, where MAP3K8 promotes myeloperoxidase activity, ROS production, and recruitment of neu-
trophils and macrophages, causing tissue damage [72]. This tissue damage and ROS production might subsequently
lead to local hypoxia which further up-regulates MAP3K8 activity, contributing to the localized hypoxia observed in
10 c© 2018 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Figure 6. Model of MAP3K8-mediated potentiation of TNF-α secretion in hypoxic inﬂammation
(1) Hypoxia inhibits PHD activity, leading to stabilization of HIF-1α. (2) HIF-1α dimerizes with HIF-1β and up-regulates MAP3K8
expression, which potentiates the p38/MAPK signaling cascade. (3) LPS-induced dimerization of TLR4 activates the p38/MAPK
signaling cascade. (4) c-JUN is phosphorylated by p-p38α and up-regulates TNF-α expression. (5) TNF-α is transported to the
plasma membrane and released.
many autoimmune diseases. In-line with this, patients suffering from systemic sclerosis and cerebrovascular inflam-
mation show clear signs of localized hypoxia, and fibroblasts from these patients showmarked increases in activation
of p38 [85–87]. In addition, MAP3K8−/− mice have reduced amounts of circulating neutrophils, which display im-
paired sensitivity to chemokines and lower TNF-α secretion [57,58]. Bone-marrow derivedDCs ofMAP3K8−/− mice
also show impaired TNF-α secretion [88] and increased IL-12 [89]. It would be interesting to study DC function in
these MAP3K8−/− mice under hypoxic conditions to confirm our in vitro findings.
In conclusion, we show that hypoxia potentiates LPS-stimulated TNF-α secretion in human moDCs by
up-regulating expression of MAP3K8, a serine/threonine kinase capable of activating the p38/MAPK signaling path-
way. Since our data provide a mechanistic link between hypoxia and immune cell function, and since these are im-
portant factors in infection, cancer, and autoimmune disease, MAP3K8 might be a promising therapeutic target for
treatment of these diseases.
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